Albany, NY -- (SBWIRE) -- 04/22/2013 -- The Biomarker Partnering Terms & Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in biomarker partnering deals
Biomarker partnering agreement structure
Biomarker partnering contract documents
Top biomarker deals by value
Most active biomarker dealmakers

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

To Buy the Copy Of This Report Visit: http://www.marketresearchreports.biz/analysis-details/biomarker-partnering-terms-and-agreements

The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 750 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by biomarker partnering company A-Z , deal type definitions and biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis/19815

Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

Biomarker Partnering Terms and Agreements includes:

Trends in biomarker dealmaking in the biopharma industry since 2007
Analysis of biomarker deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life biomarker deals
Access to several biomarker contract documents
The leading biomarker deals by value since 2007
Most active biomarker dealmakers since 2007
The leading biomarker partnering resources

In Biomarker Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Biomarker Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 750 biomarker deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise biomarker rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Related Reports:

Orphan Drugs Partnering Terms and Agreements : http://www.marketresearchreports.biz/analysis/166020

The Orphan Drugs Partnering Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in orphan drugs partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Orphan drugs partnering contract documents
Top orphan drugs deals by value

The OrphanDrugs Partnering Terms and Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies.

Partnering Deals and Alliances with Big Pharma : http://www.marketresearchreports.biz/analysis/164255

The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.

Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits:

Detailed partnering activity profiles for each of the top 50 big pharma companies
Over 300 charts showing a company’s dealmaking activity since 2005, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2005 – number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email: sales@marketresearchreports.biz
Website: http://www.marketresearchreports.biz/
Blog: http://mresearchreports.blogspot.com/